| Project/Area Number |
21592033
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NOMIYA Akira 東京大学, 医学部附属病院, 助教 (30372379)
武内 巧 東京大学, 医学部附属病院, 准教授 (90167487)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 前立腺癌 / 腎癌 / ウイルス療法 / 遺伝子治療 / 癌 |
|---|
| Research Abstract |
We constructed novel oncolytic HSV-1 using G47Δ's structure, with mutations in the ICP6, g34. 5, and a47 genes, as the basic backbone. The new virus, T-hTERT, contains a functioning ICP6 gene(encoding the large subunit of viral RR) controlled by tumor specific promoter. The in vitro replication capability of T-hTERT was higher than the control virus T-01, with an ICP6 deletion, in some and comparable to T-01 in other cell lines tested. In athymic mice bearing subcutaneous tumors, intraneoplastic injections with T-hTERT demonstrated higher efficacy than T-01 for renal cell carcinoma or prostate cancer.
|
